World News: 06:06 GMT Friday 10th August 2018. [Celltrion, Inc. via Businesswire via SPi World News]
Celltrion Inc KRX068270 is set to launch global Phase 3 clinical trial for its bevacizumab biosimilar ‘CT-P16’ for the treatment of cancer Celltrion successfully completed Phase 1 clinical study on the sa fety ...
Business Wire: 06:06 GMT Friday 10th August 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.